Full-Time

Supervisor

QC Micro

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Junior, Mid

Bridgewater Township, NJ, USA

This position may require occasional travel to partner sites in NJ or PA as business demands.

Category
Public Health
Biology Lab & Research
Biology & Biotech

You match the following Legend Biotech's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • A minimum of a Bachelor’s Degree in Science, Engineering or equivalent technical discipline is required.
  • A Minimum of 2 years relevant work experience, preferably within a biological and/or pharmaceutical industry is required.
  • Experience with aseptic processing in ISO 5 clean room and biosafety cabinets is required.
  • Knowledge of cGMP regulations and FDA/EU guidance related to manufacturing of cell-based products is required.
  • Knowledge of Good Tissue Practices is required.
  • Ability to pay attention to details and follow the procedures is required.
  • Excellent written and oral communication skill are required.
  • Candidates must be able to accommodate shift schedule. Shifts include routine weekend and evening work as required by the manufacturing process.
  • Candidates must be able to accommodate unplanned overtime (including nights and weekends) on little to no prior notice.
  • The candidate must be highly organized and capable of working in a team environment with a positive attitude under some supervision.
  • Comfortable with speaking and interacting with inspectors.
Responsibilities
  • Responsible for performing routine EM sampling, including viable/non-viable air and surface sampling, related to the manufacturing of autologous CAR-T products for clinical trials and commercial operations in a controlled cGMP cleanroom environment.
  • Work with Process Development team, Quality and Operations organization to successfully transfer process to cGMP facility to manufacture products.
  • Create, review and approve relevant QC documents, SOP’s and WI’s.
  • Ensure microbiological control strategy is consistent with cGMP requirements.
  • Participate in training and delivery of Operations aseptic technique and microbiology awareness training program.
  • Maintain, re-evaluate and communicate key critical inputs to site environmental monitoring program.
  • Perform peer review/approval of laboratory data.
  • Utilize electronic systems (LIMS) for execution and documentation of testing.
  • Perform tasks in a manner consistent with the safety policies, quality systems and cGMP requirements.
  • Other duties will be assigned, as necessary.
Desired Qualifications
  • Experience in a Quality Control setting is preferred.
  • Detailed knowledge of routine and non-routine testing and sampling methods, techniques and related equipment is preferred.
  • Detailed knowledge of the shop floor manufacturing process is preferred.
  • Comprehensive knowledge of trending using statistical analysis is preferred.
  • This position may require occasional travel to partner sites in NJ or PA as business demands.
  • This position may require up to 10% domestic or international travel as business demands.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for challenging diseases through advanced cell therapy technologies.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
  • New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
  • Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

What critics are saying

  • Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
  • Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
  • Financial strain from new R&D facility could affect operational focus if advancements lag.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

Stock Titan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).